Compare Incyte Corporation (INCY) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while State Street Real Estate Select Sector SPDR ETF trades at $45.14. Which is the better fit depends on your goals.
| INCY | XLRE | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $45.46 |
52-Week Low | $67.38 | $40.01 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $45.23, down 0.42% on the day, while maintaining a bullish technical trend per moving averages. The fund's low 0.08% expense ratio and 3.4% trailing yield appeal to cost-conscious income investors. Recent news highlights a quiet revival in REIT ETFs, with XLRE gaining 11% year-to-date as of late May 2026, defying broader rate pressures amid shifting Fed expectations.
The outlook for XLRE is cautiously optimistic, supported by solid REIT fundamentals and potential as a geopolitical hedge. Key opportunities include attractive valuations and dividend sustainability, but risks persist from interest rate volatility and inflation concerns that could pressure real estate valuations and investor sentiment in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
